• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Vector Partners Limited

    Qosina

    CMC Pharmaceuticals

    Kyongbo Pharmaceutical

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Vector Partners Limited

    Qosina

    CMC Pharmaceuticals

    Kyongbo Pharmaceutical

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    New Drug Development Strategies Needed for Alzheimer’s Treatments

    Selecting a single CRO partner that can take CNS compounds from functional screening in vitro through in vivo and beyond

    New Drug Development Strategies Needed for Alzheimer’s Treatments
    Related CONTENT
    • Charles River & CHDI Extend Partnership
    • Celgene Enters AI Drug Discovery Deal with Exscientia
    • Biogen, Eisai End Phase III aducanumab Trials in AD
    • Servier & Oncodesign Partner for Parkinson's
    • WuXi STA, Ark Biosciences Sign CMC Devt. & Mfg. Deal
    Birgit Hutter-Paier, Senior Director and Head of Neuropharmacology, QPS05.10.19
    Today, 50 million people worldwide are living with Alzheimer’s disease or a related form of dementia. That number is expected to more than triple to 152 million by 2050. 
     
    With Alzheimer’s disease becoming more prevalent by the day, it is essential the drug discovery and development industry refocus its efforts on new strategies to achieve much needed pharmaceutical breakthroughs.
     
    During the last decade, drug development for Alzheimer’s has focused primarily on treating the disease and its symptoms. It’s time we step back and focus on discovering the cause of the disease and developing drugs that delay or, ideally, prevent the onset of the Alzheimer’s.
     
    This shift is already in effect.  Today, the world’s most prominent scientists are expanding their focus beyond amyloid and tau, both playing their roles in this devastating disease, to new strategies centered around detecting Alzheimer’s while it’s in the silent biological stage. Some groups are investigating cell stress, others are investigating brain inflammation, lipid metabolism, the importance of neurofilaments or small brain lesions.  There are many promising mechanisms that could be ‘druggable;’ the focus is now on finding and testing more targets to determine how to prevent the onset of Alzheimer’s disease.
     
    Ultimately, treating Alzheimer's will likely involve a combination of therapies. For example, it could mean treating amyloid and inflammation of the brain in parallel. It’s still early days for combination therapies; however, repurposing a known drug and combining it with a new drug is one strategy that may prove successful.
     
    This is a strategy that has legs and promises even greater success as the industry receives approvals for medicines in other areas, such as for autoimmune diseases. Success with other drugs will open more doors for research in Alzheimer’s disease because we’ll have more new drugs to test as we explore new combination therapies.
     
    Regardless of which new strategies are being explored, all new compounds must move from functional screening in vitro through in vivo and beyond.  One of the biggest mistakes I see companies make as they work to advance compounds from in vitro to in vivo is testing models that aren’t closely aligned. This happens most often when companies use one partner to conduct in vitro studies and then use a different partner to conduct in vivo studies. 
     
    Working with a single CRO for early development is crucial because in vitro and follow-on in vivo studies can be designed using closely related models to, for instance, ensure the expressions of targets are the same. 
     
    The closer the in vitro model is to the in vivo model, the better the outcome. When in vitro studies are designed in a vacuum, it makes in vivo studies less predictable and the outcomes often suffer. Conversely, when companies choose a partner with proven animal models and cell models that match, the outcomes are better. For example, a mouse model expressing the same gene construct as the cell line ensures compounds are tested in in vitro and in vivo models with the same promoter, expressing the same protein fragment, with the same mutations, meaning ultimately with the same phenotype.
     
    Fortunately, we’re seeing this shift to new strategies with the hundreds of small biotech companies focused on developing potential new CNS drugs and large pharmaceutical and biotech companies continuing to demonstrate commitment to developing disease-modifying treatments for Alzheimer's.  We’re also witnessing a positive trend of more compounds moving to late-phase development as more companies choose to partner with a single high-quality CRO to ensure their in vitro and in vivo test models are closely aligned. 
     
    CRO Selection Checklist
    Don’t underestimate the importance of CRO selection. CNS drug development is a high stakes job that requires a CRO partner that can help pharmaceutical and biotech companies overcome the challenges that arise when exploring new, innovative drug development strategies and taking compounds from functional screening in vitro through in vivo and beyond.
     
    Use the CRO Selection Checklist below to help you vet CROs for your next CNS drug development project:
     
    Experience
    CRO should:
    •  Have deep experience in CNS disorders and decades of historical data to help guide your study.
    •  Have tested thousands of CNS compounds, with many of them moving to late-phase development.
    CNS Disease Models
    CRO should:
    • Have several Alzheimer's, Parkinson’s and other CNS disease models.
    • Have models that are proven to work, as evidenced by moving compounds to the next phase.
    • Excel at designing in vitro and follow-on in vivo studies using closely related models.
    Hands-On Scientists
    CRO should:
    • Have experienced scientists doing the work.
    • Have hands-on scientists who are available and equipped to make study design and testing recommendations.
    • Ensure the same team of scientists follows the study from in vitro to in vivo, making recommendations such as the duration of treatment or which positive controls to use.

    Birgit Hutter-Paier, Senior Director and Head of Neuropharmacology for QPS, established and managed the preclinical research group at QPS, which consists of highly experienced and professional members at associate and scientist levels. Hutter-Paier has extensive experience in life-science research and development, covering drug discovery and project management where she has directed multiple diverse and concurrent projects from early preclinical stage to pharmacology. During the last 15 years, her team at QPS has tested approximately 2,000 compounds specific to neurodegeneration and neuropathology, with nearly 50 of these compounds advancing to clinical development.
    Related Searches
    • alzheimer’s disease
    • quality
    • in vivo
    • it
    Suggested For You
    Charles River & CHDI Extend Partnership Charles River & CHDI Extend Partnership
    Celgene Enters AI Drug Discovery Deal with Exscientia Celgene Enters AI Drug Discovery Deal with Exscientia
    Biogen, Eisai End Phase III aducanumab Trials in AD Biogen, Eisai End Phase III aducanumab Trials in AD
    Servier & Oncodesign Partner for Parkinson Servier & Oncodesign Partner for Parkinson's
    WuXi STA, Ark Biosciences Sign CMC Devt. & Mfg. Deal WuXi STA, Ark Biosciences Sign CMC Devt. & Mfg. Deal
    AbbVie, Voyager Expand Parkinson AbbVie, Voyager Expand Parkinson's Pact
    IFM Therapeutics Launches Subsidiary IFM Therapeutics Launches Subsidiary
    Next-Gen Translational Medicine Next-Gen Translational Medicine
    QPS Expands Translational Medicine Division QPS Expands Translational Medicine Division
    Kamada Appoints R&D VP Kamada Appoints R&D VP
    QPS Launches New Brand Identity QPS Launches New Brand Identity
    NeuroBo Pharmaceuticals to Initiate Phase 3 Trial NeuroBo Pharmaceuticals to Initiate Phase 3 Trial
    Biogen Expands Neurological Disease R&D Biogen Expands Neurological Disease R&D
    Rentschler Biopharma Appoints Innovation SVP Rentschler Biopharma Appoints Innovation SVP
    Evotec & LEO Pharma Partner for Drug Discovery Evotec & LEO Pharma Partner for Drug Discovery

    Related Content

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Charles River & CHDI Extend Partnership

      Charles River & CHDI Extend Partnership

      Five-year extension of their ongoing collaboration that started in 2005 for the drug discovery and development for Huntington’s disease
      04.11.19

    • Bio News | Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | R&D
      Celgene Enters AI Drug Discovery Deal with Exscientia

      Celgene Enters AI Drug Discovery Deal with Exscientia

      Collaboration focused on accelerating drug discovery in oncology and autoimmunity
      03.25.19

    • Breaking News | Industry News
      Biogen, Eisai End Phase III aducanumab Trials in AD

      Biogen, Eisai End Phase III aducanumab Trials in AD

      Decision was based on results of a futility analysis conducted by an independent data monitoring committee
      03.22.19


    • Bio News | Collaborations & Alliances | Industry News | R&D
      Servier & Oncodesign Partner for Parkinson

      Servier & Oncodesign Partner for Parkinson's

      R&D partnership involves the LRRK2 kinase inhibitors derived from Oncodesign's proprietary Nanocyclix platform, and their potential to act against Parkinson's
      03.14.19

    • Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News | R&D
      WuXi STA, Ark Biosciences Sign CMC Devt. & Mfg. Deal

      WuXi STA, Ark Biosciences Sign CMC Devt. & Mfg. Deal

      The CDMO will provide Ark with integrated services for in process R&D and manufacturing
      03.06.19

      Trending
      • Cellipont Bioservices Expands Cell Therapy Facility | Contract Pharma
      • Biopharma Manufacturing Facility Construction | Contract Pharma
      • Next-Gen Lab Services | Contract Pharma
      • Pharma Development & Manufacturing Trends | Contract Pharma
      • Reviving Local Production Of Antibiotic Powders | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      What Are You Reading?
      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      P&G Closes HQ Due To Security Threat, Launches New Hair Care Line
      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Kimberly-Clark to Expand Diaper, Wipes Production in Brazil; The Honest Company to Sell Diapers, Wipes at Walmart & More
      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login